Microbial dysbiosis as a driver of neuroinflammation and pathology in Alzheimer's disease
微生物失调是阿尔茨海默病神经炎症和病理的驱动因素
基本信息
- 批准号:10370667
- 负责人:
- 金额:$ 43.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-15 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:3xTg-AD mouseAblationAddressAffectAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease patientAmyloid beta-ProteinAmyloidosisAnimal ModelAntibioticsAtlasesBiological FactorsBrainBrain PathologyChronicClinical ResearchCommunitiesDataDerivation procedureDiseaseDisease ProgressionFutureGenerationsGerm-FreeHumanHuman MicrobiomeImmuneImmune responseImmune systemImmunityKnowledgeLaboratoriesMusNerve DegenerationNeurodegenerative DisordersPathogenesisPathologyPeripheralProbioticsProcessProductionResearchRoleSamplingSerumSeverity of illnessSplenocyteStudy modelsTauopathiesTestingTransplantationWaterWorkabeta depositionage relatedcognitive performancecost effectivedysbiosisfecal microbiotafecal transplantationgerm free conditiongut microbiotahuman microbiotahuman modelimmunoregulationliquid chromatography mass spectrometrymetabolomemetabolomicsmicrobialmicrobiomemicrobiotamicrobiota transplantationmouse modelnervous system disorderneuroinflammationoverexpressionprospectivereconstitutionsexsingle-cell RNA sequencingtherapeutic targettranslational potential
项目摘要
ABSTRACT
Recent advances have helped to uncover critical roles for gut microbiota in a spectrum of neurological disorders
including many neurodegenerative diseases. In the case of Alzheimer’s disease (AD), it has been shown in both
AD patients and animal models that neurodegenerative disease progression is associated with large-scale
changes in gut microbiota composition. Moreover, recent data also suggest that ablation of the microbiome with
either germ-free re-derivation or chronic treatment with broad-spectrum antibiotics water limits amyloidosis in
mice that over-express amyloid beta (Ab). While these findings have led to excitement over the potential role for
microbial dysbiosis in AD, numerous fundamental questions still remain to be answered on this topic. For one,
all of these previous studies have only explored the impact of the murine microbiome on neurodegenerative
disease and have not investigated how the specific dysbiosis seen in AD patients affects neurological disease
progression. Given the major differences that exist between the mouse and human microbiome, it will be
important to specifically probe how alterations in human gut microbiota influence neurodegenerative disease
processes. In addition, little is currently known regarding how microbial dysbiosis affects tauopathy. To fill these
gaps in knowledge, we will transplant gut microbiota from either AD patients or age- and sex-matched controls
into germ-free 3xTg-AD mice, which is a well-described mouse model of AD that develops age-related and
progressive Ab-induced neurological disease and tauopathy. The impact of human AD-associated dysbiosis on
disease progression will then be determined by evaluating Ab deposition, tauopathy, neurodegeneration,
neuroinflammation, and cognitive performance (Aim 1). Recent studies in other non-AD models of
neurodegenerative disease suggest that the gut microbiota can influence disease progression via modulation of
the immune system and/or by promoting changes in metabolite generation. Therefore, in our second Aim, we
will next leverage cutting-edge single-cell RNA-sequencing (scRNA-seq) and metabolomics approaches to
provide a comprehensive and unbiased assessment of how AD-associated dysbiosis affects immune responses
and the metabolome in our human microbiota transplantation AD mouse model. Our overarching hypothesis is
that microbial dysbiosis in AD patients leads to exacerbated neurodegenerative disease progression and that
this is associated with dysregulation of immune responses and the metabolome. Successful completion of these
proposed research directions will break new ground in our understanding of the role of AD-associated dysbiosis
in neurodegenerative disease pathogenesis and will also begin to reveal prospective factors underpinning the
effects of the human AD microbiome on disease progression. Furthermore, findings from these studies are of
potential translational significance as they could help to establish the microbiome as a therapeutic target to
pursue in the treatment of AD.
摘要
最近的进展有助于揭示肠道微生物群在一系列神经系统疾病中的关键作用
包括许多神经退行性疾病。在阿尔茨海默病(AD)的情况下,它已被证明在两个
AD患者和动物模型表明,神经退行性疾病进展与大规模的
肠道微生物群组成的变化。此外,最近的数据还表明,
无论是无菌再衍生还是用广谱抗生素长期治疗,
过表达淀粉样蛋白β(Ab)的小鼠。虽然这些发现引起了对潜在作用的兴奋,
尽管AD中存在微生物生态失调,但关于该主题的许多基本问题仍有待回答。首先,
所有这些先前的研究仅探索了鼠微生物组对神经退行性疾病的影响。
目前还没有研究在AD患者中观察到的特定生态失调如何影响神经系统疾病
进展鉴于小鼠和人类微生物组之间存在的主要差异,
重要的是要专门探讨人类肠道微生物群的改变如何影响神经退行性疾病
流程.此外,目前对微生物生态失调如何影响tau蛋白病知之甚少。填补这些
我们将从AD患者或年龄和性别匹配的对照组中移植肠道微生物群,
无菌3xTg-AD小鼠,这是一种描述良好的AD小鼠模型,其发展与年龄相关的,
进行性Ab诱导的神经系统疾病和tau蛋白病。人类AD相关的生态失调对
然后通过评估Ab沉积、tau蛋白病、神经变性
神经炎症和认知表现(目标1)。其他非AD模型的最新研究
神经退行性疾病表明,肠道微生物群可以通过调节
免疫系统和/或通过促进代谢物产生的变化。因此,在第二个目标中,我们
下一步将利用尖端的单细胞RNA测序(scRNA-seq)和代谢组学方法,
对AD相关的生态失调如何影响免疫反应提供全面和公正的评估
和代谢组在我们的人类微生物群移植AD小鼠模型。我们的首要假设是
AD患者的微生物生态失调导致神经退行性疾病恶化,
这与免疫反应和代谢组的失调有关。成功完成这些
提出的研究方向将为我们理解AD相关生态失调的作用开辟新的天地
并将开始揭示支持神经退行性疾病发病机制的前瞻性因素。
人类AD微生物组对疾病进展的影响。此外,这些研究的结果是
潜在的翻译意义,因为它们可以帮助建立微生物组作为治疗靶点,
在AD的治疗中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John R Lukens其他文献
Harnessing microglia-based cell therapies for the treatment of neurodegenerative diseases
利用基于小胶质细胞的细胞疗法治疗神经退行性疾病
- DOI:
10.1016/j.coi.2025.102552 - 发表时间:
2025-06-01 - 期刊:
- 影响因子:5.800
- 作者:
Adeline E Walsh;John R Lukens - 通讯作者:
John R Lukens
John R Lukens的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John R Lukens', 18)}}的其他基金
CLEC7A in microglia biology and Alzheimer's disease
CLEC7A 在小胶质细胞生物学和阿尔茨海默病中的作用
- 批准号:
10659940 - 财政年份:2023
- 资助金额:
$ 43.47万 - 项目类别:
Role of the SYK-CARD9 signaling axis in Alzheimer's disease
SYK-CARD9 信号轴在阿尔茨海默病中的作用
- 批准号:
10198453 - 财政年份:2021
- 资助金额:
$ 43.47万 - 项目类别:
Delineating the effects of sex on microglia in neurodevelopmental disorders
描述性别对神经发育障碍中小胶质细胞的影响
- 批准号:
9809266 - 财政年份:2019
- 资助金额:
$ 43.47万 - 项目类别:
Inflammasome activation and lymphatic dysfunction in traumatic brain injury
创伤性脑损伤中的炎症小体激活和淋巴功能障碍
- 批准号:
10459460 - 财政年份:2018
- 资助金额:
$ 43.47万 - 项目类别:
Inflammasome activation and lymphatic dysfunction in traumatic brain injury
创伤性脑损伤中的炎症小体激活和淋巴功能障碍
- 批准号:
10222790 - 财政年份:2018
- 资助金额:
$ 43.47万 - 项目类别:
Inflammasome activation and lymphatic dysfunction in traumatic brain injury
创伤性脑损伤中的炎症小体激活和淋巴功能障碍
- 批准号:
9977266 - 财政年份:2018
- 资助金额:
$ 43.47万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 43.47万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 43.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 43.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 43.47万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 43.47万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 43.47万 - 项目类别:
Continuing Grant
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 43.47万 - 项目类别:
Fellowship
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 43.47万 - 项目类别:
Continuing Grant
Cryo laser-ablation system (157+193nm) with 'triple-quad' plasma mass spectrometer, Cryo-LA-ICPMS/MS
带有“三重四极杆”等离子体质谱仪、Cryo-LA-ICPMS/MS 的冷冻激光烧蚀系统 (157 193nm)
- 批准号:
515081333 - 财政年份:2023
- 资助金额:
$ 43.47万 - 项目类别:
Major Research Instrumentation
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 43.47万 - 项目类别:
Standard Grant